Back To TOP

Learn About Us

At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.




  • Last year, we helped more than 100,000 fully insured, underinsured and uninsured patients with access issues
  • Every year, we support privately insured patients through our co-pay card programs
  • We have supported co-pay assistance foundations with more than $932* million in donations since 2005
  • Since 1985, when its first product was approved, Genentech has donated $3.50 billion in free medicine through the Genentech® Access to Care Foundation (GATCF) and other product donation programs


ZELBORAF Access Solutions

ZELBORAF Access Solutions offers a full range of programs and services to meet the needs of patients and health care professionals. We provide what patients need for access, from benefits investigations through patient assistance options.Learn more


* Amount is approximate pending final financial audit confirmation; data published in March 2013.
GATCF donation value is based on the most current forecast.

Watch the
Tutorial Video


Learn More About
  • LEARN about treatment with Zelboraf
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for ZELBORAF
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information

ZELBORAF Indication and Important Safety Information


ZELBORAF® (vemurafenib) tablets are indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

ZELBORAF is not indicated for use in patients with wild-type BRAF melanoma.

Important Safety Information

The following can occur in patients treated with ZELBORAF:

  • New primary malignancies including cutaneous squamous cell carcinoma, non-cutaneous squamous cell carcinoma, new primary melanoma, and other malignancies
  • Tumor promotion in BRAF wild-type melanomas
  • Serious hypersensitivity reactions including anaphylaxis
  • Severe dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
  • QT prolongation
  • Hepatotoxicity including liver laboratory abnormalities, and, when concurrently administered with ipilimumab, increases in transaminases and bilirubin
  • Photosensitivity
  • Ophthalmologic reactions

ZELBORAF can cause fetal harm when administered to a pregnant woman based on its mechanism of action.

The most common adverse reactions of any grade (≥30%) reported were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma.

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

Please see accompanying full Prescribing Information for additional important safety information.

ZELBORAF® and the Access Solutions logo are registered trademarks of Genentech, Inc.